Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;5(1):11.
doi: 10.1186/s40345-017-0080-x. Epub 2017 May 8.

Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression

Affiliations
Review

Lithium in the episode and suicide prophylaxis and in augmenting strategies in patients with unipolar depression

Mohammed T Abou-Saleh et al. Int J Bipolar Disord. 2017 Dec.

Abstract

Background: Depressive disorders are a leading cause of the global burden of disease and are associated with high recurrent often continuing morbidity and high excess mortality by suicide and cardiovascular disease. Whilst there are established, effective and cost-effective treatments for depression, their long-term management is often neglected: there is continuing controversy over the case of need for long-term treatment including lifelong treatment and safety issues.

Objective and methods: In this narrative review, we critically examine the evidence for the effectiveness and safety of lithium salts in the long-term management of unipolar depression. We refer to existing recent international guidelines as well as the scientific literature selectively and against the background of our longstanding experience with patients suffering from unipolar depression who are often under treated or inappropriately treated.

Results and discussion: According to many studies mostly dating back to the 1970/1980s, lithium is efficacious in the prophylaxis of unipolar depression particularly depression with melancholia and delusional depression and showing a clearly episodic course. Also the efficacy of lithium maintenance treatment following recovery by ECT has been clearly shown. Moreover, convincing evidence exists that lithium has added value and benefit for its unique anti-suicidal effects as well as reducing mortality by other causes. The anti-suicidal effect has been convincingly demonstrated in bipolar as well as in unipolar patients. Nevertheless its use in the management of patients with unipolar depression has not been properly recognized by a majority of textbooks and guidelines. Whilst it has been well considered as an effective treatment for depression that has not responded to antidepressants as an adjunct treatment, also called augmentation, it has been much less recommended for the prevention of recurrent episodes of unipolar depression. One of the reasons for this neglect is the blurring of the diagnosis "unipolar depression" by modern diagnostic tools. Lithium will hardly work in a patient with "unipolar depression spectrum disease".

Conclusions: We conclude that lithium is an effective prophylactic treatment for carefully selected patients with unipolar depression and is safe when prescribed in recommended doses/plasma lithium levels and with regular, careful monitoring. We propose that lithium prophylaxis can be indicated in patients with unipolar depression and that the occurrence of 2 episodes of depression within 5 years is a practical criterion for starting lithium prophylaxis particularly in severe depression with psychotic features and high suicidal risk. Furthermore, an indication might be considered especially in unipolar patients in whom a bipolar background is suspected. In some cases, lithium prophylaxis may be recommended after a single episode of depression that is severe with high suicidal risk and continued life-long.

Keywords: Antisuicidal effect; Augmentation; ECT; Lithium; Long-term-prophylaxis; Unipolar depression.

PubMed Disclaimer

Similar articles

Cited by

  • Clinical use of lithium salts: guide for users and prescribers.
    Tondo L, Alda M, Bauer M, Bergink V, Grof P, Hajek T, Lewitka U, Licht RW, Manchia M, Müller-Oerlinghausen B, Nielsen RE, Selo M, Simhandl C, Baldessarini RJ; International Group for Studies of Lithium (IGSLi). Tondo L, et al. Int J Bipolar Disord. 2019 Jul 22;7(1):16. doi: 10.1186/s40345-019-0151-2. Int J Bipolar Disord. 2019. PMID: 31328245 Free PMC article. Review.
  • The Combination of Lithium and ACE Inhibitors: Hazardous, Critical, Possible?
    Hommers L, Fischer M, Reif-Leonhard C, Pfuhlmann B, Deckert J, Unterecker S. Hommers L, et al. Clin Drug Investig. 2019 May;39(5):485-489. doi: 10.1007/s40261-019-00768-7. Clin Drug Investig. 2019. PMID: 30805791
  • The Syndrome of Irreversible Lithium-Effectuated Neurotoxicity: A Scoping Review.
    Konieczny K, Detraux J, Bouckaert F. Konieczny K, et al. Alpha Psychiatry. 2024 Mar 1;25(2):190-205. doi: 10.5152/alphapsychiatry.2024.231460. eCollection 2024 Mar. Alpha Psychiatry. 2024. PMID: 38798809 Free PMC article.
  • Association of polygenic score for major depression with response to lithium in patients with bipolar disorder.
    Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Cearns M, Heilbronner U, Degenhardt F, Tekola-Ayele F, Hsu YH, Shekhtman T, Adli M, Akula N, Akiyama K, Ardau R, Arias B, Aubry JM, Backlund L, Bhattacharjee AK, Bellivier F, Benabarre A, Bengesser S, Biernacka JM, Birner A, Brichant-Petitjean C, Cervantes P, Chen HC, Chillotti C, Cichon S, Cruceanu C, Czerski PM, Dalkner N, Dayer A, Del Zompo M, DePaulo JR, Étain B, Jamain S, Falkai P, Forstner AJ, Frisen L, Frye MA, Fullerton JM, Gard S, Garnham JS, Goes FS, Grigoroiu-Serbanescu M, Grof P, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jiménez E, Kahn JP, Kassem L, Kuo PH, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicki S, König B, Kusumi I, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Tortorella A, Manchia M, Martinsson L, McCarthy MJ, McElroy SL, Colom F, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Novák T, O'Donovan C, Ozaki N, Ösby U, Pfennig A, Potash JB, Reif A; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium; Reininghaus E, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schweizer BW, Severino G, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Squas… See abstract for full author list ➔ Amare AT, et al. Mol Psychiatry. 2021 Jun;26(6):2457-2470. doi: 10.1038/s41380-020-0689-5. Epub 2020 Mar 16. Mol Psychiatry. 2021. PMID: 32203155
  • Effects of ebselen addition on emotional processing and brain neurochemistry in depressed patients unresponsive to antidepressant medication.
    Ramli FF, Singh N, Emir UE, Villa LM, Waters S, Harmer CJ, Cowen PJ, Godlewska BR. Ramli FF, et al. Transl Psychiatry. 2024 May 7;14(1):200. doi: 10.1038/s41398-024-02899-8. Transl Psychiatry. 2024. PMID: 38714646 Free PMC article. Clinical Trial.

References

    1. Abou-Saleh MT, Coppen AJ. Continuation therapy with antidepressants after electroconvulsive therapy. Convuls Ther. 1988;4(4):263–268. - PubMed
    1. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord. 1986;10(2):115–125. doi: 10.1016/0165-0327(86)90034-0. - DOI - PubMed
    1. Abou-Saleh MT, Coppen A. Classification of depression and response to antidepressive therapies. Br J Psychiatry. 1983;143:601–603. doi: 10.1192/bjp.143.6.601. - DOI - PubMed
    1. Abou-Saleh MT. How long should drug therapy for depression be maintained? Am J Psychiatry. 1987;144(9):1247–1248. - PubMed
    1. Ahrens B, Müller-Oerlinghausen B, Schou M, Wolf T, Alda M, Grof E, Grof P, Lenz G, Simhandl C, Thau K, Vestergaard P, Wolf R, Möller H-J. Excess cardiovascular and suicide mortaility of affective disorders may be reduced by lithium prophylaxis. J Affect Disord. 1995;33:67–75. doi: 10.1016/0165-0327(94)00074-J. - DOI - PubMed